Multicenter, open-label, single dose study to evaluate safety, tolerability and pharmacokinetics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction.
EntrestoPeds
What is the goal of the study?
To learn more about this study, please email the study team member listed below.
Who can participate in the study?
Please contact the study team listed below to learn more.